BioCardia wants to gauge whether it has enough evidence to pursue regulatory approval for CardiAMP in ischemic heart failure.

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...

The financing will in part support development of the firm's PI3K inhibitor paxalisib in PIK3CA-mutated brain cancer and HER2-positive breast cancer.

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

NEW YORK – Silexion Therapeutics on Thursday announced the immediate exercise of certain outstanding warrants to purchase its ordinary shares, allowing it to raise gross proceeds of $1.8 million. The ...